Inventor · disambiguated record
Roberto Carlos Bravo González
Also filed as: BRAVO GONZALEZ ROBERTO CARLOS · BRAVO GONZALÉZ ROBERTO CARLOS · BRAVO GONZÁLEZ ROBERTO CARLOS
20 granted patents·6 pending applications·41 citations·filing 2013–2025
92Inventor score
Top patents by PatentIndex Score
26 records- 0193US11534406B2Delayed release drug formulationTILLOTTS PHARMA AG·Filed 2020·Granted Dec 27, 2022·3 cites·27 claims
- 0288US10226430B2Delayed release drug formulationTILLOTTS PHARMA AG·Filed 2013·Granted Mar 12, 2019·10 cites·33 claims
- 0387US11517534B2Delayed release drug formulationTILLOTTS PHARMA AG·Filed 2017·Granted Dec 6, 2022·2 cites·31 claims
- 0487US11266605B2Modified release coated capsulesTILLOTTS PHARMA AG·Filed 2015·Granted Mar 8, 2022·3 cites·14 claims
- 0586US10272048B2Delayed release drug formulationTILLOTTS PHARMA AG·Filed 2016·Granted Apr 30, 2019·4 cites·7 claims
- 0686US9814681B2Delayed release drug formulationTILLOTTS PHARMA AG·Filed 2013·Granted Nov 14, 2017·6 cites·46 claims
- 0786US9364440B2Delayed release drug formulationTILLOTTS PHARMA AG·Filed 2013·Granted Jun 14, 2016·8 cites·50 claims
- 0883US11529326B2Eflornithine and sulindac, fixed dose combination formulationCANCER PREVENTION PHARMACEUTICALS INC·Filed 2021·Granted Dec 20, 2022·1 cites·20 claims
- 0982US12350246B2Eflornithine and sulindac, fixed dose combination formulationCANCER PREVENTION PHARMACEUTICALS INC·Filed 2024·Granted Jul 8, 2025·0 cites·13 claims
- 1077US11925613B2Eflornithine and sulindac, fixed dose combination formulationCANCER PREVENTION PHARMACEUTICALS INC·Filed 2022·Granted Mar 12, 2024·0 cites·19 claims
- 1175US10391061B2Delayed release pharmaceutical formulation and methods of making and using sameTILLOTTS PHARMA AG·Filed 2018·Granted Aug 27, 2019·2 cites·13 claims
- 1274US10799515B2Delayed release drug formulationTILLOTTS PHARMA AG·Filed 2013·Granted Oct 13, 2020·1 cites·50 claims
- 1369US2025127722A1Solid oral dosage form comprising antibodies for sustained release in the lower gastrointestinal tractTILLOTTS PHARMA AG·Filed 2024·Application pending·0 cites
- 1468US2024000714A1Topical treatment of inflammatory bowel disease using antibodies and fragments thereofTILLOTTS PHARMA AG·Filed 2023·Application pending·0 cites
- 1567US11998641B2Modified release coated capsulesTILLOTTS PHARMA AG·Filed 2021·Granted Jun 4, 2024·0 cites·10 claims
- 1667US9895314B2Delayed release pharmaceutical formulation containing porous carrier particles for colon targetingTILLOTTS PHARMA AG·Filed 2014·Granted Feb 20, 2018·1 cites·12 claims
- 1765US12370147B2Coatable core for a modified release drug formulationTILLOTTS PHARMA AG·Filed 2019·Granted Jul 29, 2025·0 cites·12 claims
- 1862US10973790B2Eflornithine and sulindac, fixed dose combination formulationCANCER PREVENTION PHARMACEUTICALS INC·Filed 2016·Granted Apr 13, 2021·0 cites·23 claims
- 1961US11717484B2Topical treatment of inflammatory bowel disease using antibodies and fragments thereofTILLOTTS PHARMA AG·Filed 2018·Granted Aug 8, 2023·0 cites·13 claims
- 2060US2025302755A1Coatable core for a modified release drug formulationTILLOTTS PHARMA AG·Filed 2025·Application pending·0 cites
- 2153US2022016037A1Colonic drug delivery formulationTILLOTTS PHARMA AG·Filed 2019·Application pending·0 cites
- 2248US12370146B2Method of producing a delayed release drug formulationTILLOTTS PHARMA AG·Filed 2019·Granted Jul 29, 2025·0 cites·20 claims
- 2348US2016287521A1Multi-particulate drug delivery systemTILLOTTS PHARMA AG·Filed 2014·Application pending·0 cites
- 2445US10179105B2Microgel particles containing nanotubes loaded with an active pharmaceutical ingredientTILLOTTS PHARMA AG·Filed 2016·Granted Jan 15, 2019·0 cites·12 claims
- 2545US2022016038A1Colonic drug delivery formulationTILLOTTS PHARMA AG·Filed 2019·Application pending·0 cites
- 2642US11160762B2Modified release coated capsulesTILLOTTS PHARMA AG·Filed 2015·Granted Nov 2, 2021·0 cites·12 claims
Join the waitlist — get patent alerts
Get an alert when Roberto Carlos Bravo González files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →